Navigation Links
Transvaginal Mesh Makers in the Hot Seat reports Life Care Solutions Group
Date:12/27/2013

CONCORD, Calif., Dec. 27, 2013 /PRNewswire/ -- Women who have been injured by transvaginal mesh products are becoming increasingly aware of their legal options to recover compensation from makers of transvaginal mesh products. For years, the pain and suffering of patients who have been treated with these medical devices seemed like a well kept secret; however, since the initial release of information by the FDA in 2008 about the associated risks, more manufacturers of these products are finding themselves in hot water over the release of these dangerous devices into the market.

Implanted for the treatment of pelvic organ prolapse and stress urinary incontinence, transvaginal mesh implant surgery was once widely believed to be beneficial to provide support for weakened pelvic floor muscles. Even after the FDA's public health notification about reported complications suffered by thousands of women, many more continued to undergo transvaginal mesh surgical procedures without fully understanding the risks.

Transvaginal Mesh or Sling Products
"The Transvaginal Mesh, or Sling disaster may involve 10,000's of US women with severe injuries... According to the New York Times, in 2010, about 185,000 women underwent procedures in which mesh was implanted vaginally to treat urinary incontinence. That is 2010 alone."

For more information about transvaginal mesh or sling injuries, please visit http://usdrugwatchdog.com/transvaginal.htm

Again in 2011, the FDA released a communication citing several additional reports of health problems linked to POP and SUI mesh repairs.

FDA Safety Communication: UPDATE on Serious Complications Associated with Transvaginal Placement of Surgical Mesh for Pelvic Organ Prolapse

In order to better understand the use of surgical mesh for POP and SUI, the FDA conducted a systematic review of the published scientific literature from 1996 – 2011 to evaluate its safety and effectiveness. The review showed that transvaginal POP repair with mesh does not improve symptomatic results or quality of life over traditional non-mesh repair. The FDA continues to evaluate the literature for SUI surgeries using surgical mesh and will report about that usage at a later date.

For more information about the FDA's update on complication associated with the surgical mesh, please visit http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm262435.htm

Among the manufacturers named in lawsuits filed on behalf of injured vaginal mesh surgery patients are Johnson & Johnson, C.R. Bard, AMS, and Boston Scientific. Several victims have already won bellwether cases against the companies, and many more are pending.

The Life Care Solutions Group is available to help women who have been injured by a transvaginal mesh device and have questions about their medical and legal options. Those who need help can contact the group for more information today.

Greg A. Vigna
888.855.1674


'/>"/>
SOURCE Life Care 123 LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Transvaginal Mesh Surgery and Organ Perforation: The Dangerous Connection
2. What Are the Warning Signs of a Failing Transvaginal Mesh Device?
3. Obtaining a Free Transvaginal Mesh Lawsuit Review
4. Transvaginal Mesh Settlement Funding Amounts Increased At Legal-Bay
5. Transvaginal Mesh Settlement Funding News: Legal-Bay To Increase Funding Amounts Up to $250K On Some Vaginal Mesh and Bladder Sling Recall Cases
6. DePuy Settlement Funding And Transvaginal Mesh Capital Increased At Legal-Bay
7. DePuy & Transvaginal Mesh Lawsuit Settlement Funding Leads Legal-Bay to Banner 2nd Quarter
8. Pharmspective Launches Affordable Care Act eLearning for Healthcare Decision-Makers
9. Global Cardiac Pacemakers - Market Growth Analysis, 2009-2015
10. Aratana Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... An April 24th article on Yahoo! ... 180 pounds with the help of a weight loss surgery. The woman, declaring “I will ... that have been left following her dramatic weight loss. Dr. Feiz & Associates notes that, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading provider ... Online(TM), which enables sleep physicians to create and edit their interpretation reports. This ... provides a familiar interface that does not require additional training to use. It ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic ... has joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board ... Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is ...
(Date:4/28/2017)... Ca (PRWEB) , ... April 28, 2017 , ... ... cardiac or hERG liability could substantially improve drug safety and minimize the cost ... provided for validating ion channel inhibition using cell lines and for cardiac toxicity ...
Breaking Medicine News(10 mins):